Polyphor successfully completes Phase I study with POL6014
6 June 2016 | By Victoria White, Digital Content Producer
POL6014 is a highly selective, potent and reversible inhibitor of hNE. Increased levels of hNE is associated with cystic fibrosis...
List view / Grid view
News
Merck releases new data for Keytruda at ASCO
6 June 2016 | By Victoria White, Digital Content Producer
Keytruda is a humanised monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells...
Experts analyse growth in the finished dosage market ahead of CPhI Worldwide launch
6 June 2016 | By CPhI
The new Finished Dosage Formulation (FDF) event will be the first global pharma platform dedicated to the manufacture, development and supply of finished dosage forms...
Dupilumab + TCS superior to TCS alone in treating atopic dermatitis
6 June 2016 | By Victoria White, Digital Content Producer
Sanofi and Regeneron have announced that a one-year Phase III study evaluating investigational dupilumab met its primary and key secondary endpoints.
IMAB362 extends survival in gastric cancer
6 June 2016 | By Victoria White, Digital Content Producer
Ganymed announced data from its randomised Phase II clinical study of IMAB362 in first-line treatment of gastric cancer at the ASCO 2016 Annual Meeting...
Data for Alimta and Cyramza plus keytruda in NSCLC presented at ASCO
6 June 2016 | By Victoria White, Digital Content Producer
Data were presented from two early-phase trials evaluating Lilly's Alimta and Cyramza in combination with Merck's Keytruda in patients with NSCLC...
BMS presents new data for Opdivo at ASCO
6 June 2016 | By Victoria White, Digital Content Producer
New data for Bristol-Myers Squibb’s Opdivo has been presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)...
Daratumumab extends PFS in patients with multiple myeloma
6 June 2016 | By Victoria White, Digital Content Producer
Daratumumab, in combination with bortezomib and dexamethasone, demonstrated a 61% reduction in the risk of disease progression or death...
Immunotherapy shrinks tumours in neuroblastoma patients
3 June 2016 | By Victoria White, Digital Content Producer
Neuroblastoma tumours shrank in 80% of young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody...
Shire and Baxalta combine to create a global leader in rare diseases
3 June 2016 | By Victoria White, Digital Content Producer
Shire and Baxalta have combined businesses, creating a leading global company focused on rare diseases and other highly specialised conditions...
Bayer and Orion expand BAY-1841788 programme in prostate cancer
3 June 2016 | By Victoria White, Digital Content Producer
The Phase III study ARASENS will evaluate BAY-1841788 in men with newly diagnosed metastatic hormone-sensitive prostate cancer...
Early response to Saxenda results in improvement in weight loss
3 June 2016 | By Victoria White, Digital Content Producer
Three-year data show early response to Novo Nordisk’s Saxenda (liraglutide 3 mg) resulted in improvements in weight loss and cardiometabolic risk factors...
FDA approves Ocaliva for primary biliary cholangitis
3 June 2016 | By Victoria White, Digital Content Producer
The FDA has granted accelerated approval to Intercept Pharmaceuticals’ Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis...
AstraZeneca licenses gout drug Zurampic to Grünenthal
2 June 2016 | By Victoria White, Digital Content Producer
Grünenthal has entered into a licensing agreement with AstraZeneca for the exclusive rights to Zurampic (lesinurad) in Europe and Latin America...
New version of Clarity Chromatography Software expands portfolio of controlled instruments and introduces new features
2 June 2016 | By DataApex
Clarity version 7.0 has the reorganized installation structure, which allows better access to data and a new robust system of custom units...
